Garching / Munich, February 25, 2026 – (ITM), a leading radiopharmaceutical biotech company, today announced it will present further exploratory and post-hoc subgroup analysis data focused on Pancreatic Neuroendocrine Tumors from its Phase 3 COMPETE trial in an oral presentation at the 23rd Annual European Neuroendocrine Tumor Society (ENETS) Conference, held from March 4 – March 6, 2026 in Kraków, Poland. The company will additionally host a conference booth (#6) and an interactive symposium on March 5, 2026, convening leading experts in radiopharmaceutical oncology to share their views on key challenges and emerging clinical approaches for the treatment of neuroendocrine tumors (NETs).
Oral Presentation Details
Title: 177Lu-edotreotide for the Treatment of Pancreatic Neuroendocrine Tumours: A Subgroup Analysis from the COMPETE Study
Presentation ID: D54
Session: Clinical science | Session 2B: Abstract session
Date and Time: Thursday, March 5, 11:50–11:57 AM (CET)
Location: Theatre Hall S2, ICE Kraków Congress Centre
Presenter: Prof. Dr. Thomas Walter, Medical Oncologist, Lyon, France
Satellite Symposium Details
Title: Vote and Learn: Radiopharmaceutical Therapy in NETs
Date and Time: Thursday, March 5, 07:45–08:45 AM (CET)
Location: Theatre Hall S2, ICE Kraków Congress Centre
Presenters: Dr. Francesca Spada, Medical Oncologist, Milano, Italy; Prof. Christophe Deroose, Nuclear Medicine Physician, Leuven, Belgium; Prof. Simron Singh, Medical Oncologist, Toronto, Canada
About the COMPETE Trial
The COMPETE trial (NCT03049189) evaluated 177Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic investigational agent against everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This trial achieved its primary endpoint, with 177Lu-edotreotide showing a clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus. 177Lu-edotreotide is an investigational product under review by the U.S. Food and Drug Administration (FDA) and is not approved by any regulatory authority for safety and/or efficacy in any intended use. It is also being evaluated in COMPOSE, a Phase 3 study in patients with well-differentiated, aggressive Grade 2 or Grade 3, somatostatin receptor (SSTR)-positive GEP-NET tumors.
About ITM Isotope Technologies Munich SE
ITM, a leading radiopharmaceutical biotech company, is dedicated to delivering a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians, and our partners through excellence in the development, production, and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all our actions, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, by combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position, and established global network, ITM strives to provide patients with more effective targeted treatments to enhance clinical outcomes and quality of life.
ITM Contact
Corporate Communications
Kathleen Noonan/Julia Westermeir
Phone: +49 89 329 8986 1500
Email:
Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email:
Attachment
